Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Apellis Pharmaceuticals stock | 38.43

Own Apellis Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Apellis Pharmaceuticals, Inc is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 297 staff and has a market cap (total outstanding shares value) of USD$2.5 billion.

How to buy shares in Apellis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Apellis Pharmaceuticals. Find the stock by name or ticker symbol: APLS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Apellis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$38.43, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Apellis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Apellis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Apellis Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Apellis Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$38.43, which is 4.06% up on its pre-crash value of USD$36.87 and 128.07% up on the lowest point reached during the March crash when the shares fell as low as USD$16.85.

If you had bought USD$1,000 worth of Apellis Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$550.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$885.43.

Apellis Pharmaceuticals share price

Use our graph to track the performance of APLS stocks over time.

Apellis Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$38.43
52-week range USD$16.85 - USD$45.04
50-day moving average USD$31.8723
200-day moving average USD$31.3771
Wall St. target price USD$51.62
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.322

Buy Apellis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Apellis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Apellis Pharmaceuticals price performance over time

Historical closes compared with the close of $38.43 from 2020-11-16

1 week (2020-11-18) -7.58%
1 month (2020-10-26) 7.17%
3 months (2020-08-25) 32.93%
6 months (2020-05-22) 10.15%
1 year (2019-11-25) 36.86%
2 years (2018-11-23) 138.55%
3 years (2017-11-24) 182.57%
5 years (2015-11-22) N/A

Apellis Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -41.1%
Return on equity TTM -240.56%
Profit margin 0%
Book value $3.07
Market capitalisation USD$2.5 billion

TTM: trailing 12 months

Shorting Apellis Pharmaceuticals shares

There are currently 10.9 million Apellis Pharmaceuticals shares held short by investors – that's known as Apellis Pharmaceuticals's "short interest". This figure is 3.8% up from 10.5 million last month.

There are a few different ways that this level of interest in shorting Apellis Pharmaceuticals shares can be evaluated.

Apellis Pharmaceuticals's "short interest ratio" (SIR)

Apellis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Apellis Pharmaceuticals shares currently shorted divided by the average quantity of Apellis Pharmaceuticals shares traded daily (recently around 622651.2). Apellis Pharmaceuticals's SIR currently stands at 17.5. In other words for every 100,000 Apellis Pharmaceuticals shares traded daily on the market, roughly 17500 shares are currently held short.

However Apellis Pharmaceuticals's short interest can also be evaluated against the total number of Apellis Pharmaceuticals shares, or, against the total number of tradable Apellis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Apellis Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Apellis Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.221% of the tradable shares (for every 100,000 tradable Apellis Pharmaceuticals shares, roughly 221 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Apellis Pharmaceuticals.

Find out more about how you can short Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals share dividends

We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.

Apellis Pharmaceuticals share price volatility

Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $16.85 up to $45.04. A popular way to gauge a stock's volatility is its "beta".

APLS.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.1483. This would suggest that Apellis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Apellis Pharmaceuticals overview

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site